• Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology
• Positive CHMP opinion based on comprehensive analytical, preclinical and clinical data package that shows proposed biosimilar adalimumab matches reference medicine
• This recommendation marks the fourth positive CHMP opinion for a Sandoz biosimilar within 18 months

Holzkirchen, June 1, 2018 – Sandoz, a Novartis division and the global leader in biosimilars, …